Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.

Paul LesueurAlexandre EscandeJuliette ThariatEnora VauléonIsabelle MonnetAlexis CortotDelphine LerougeSerge DanhierPascal DôCatherine Dubos-ArvisChristos ChouaidRadj Gervais

Published in: Cancer medicine (2018)

Radiotherapy delivered during the 6 months before, during, or the three months following nivolumab for NSCLCs was not associated with an increased risk of severe or unexpected toxicities.

Keyphrases

early stage
radiation therapy
locally advanced
early onset
squamous cell carcinoma
drug induced
rectal cancer